BENZOPHENONE-3

2 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funder: Natural Science Foundation of Zhejiang Province

Humans1
Animals1

Outcomes

MAPK/ERK signalling

upin human cells1

1 study

BENZOPHENONE-3 activates MAPK/ERK signalling in human cells.
“BP-3 exposure selectively activated ERK1/2 pathway but not p38 or JNK pathways within the MAPK cascade”
Cellsin vitro
Benzophenone-3 drives osteoarthritis pathogenesis by regulating chondrocyte senescence
Chemico-biological interactions30 Sep 2025